Ligand validation:5HF9

PE8: 3,6,9,12,15,18,21-HEPTAOXATRICOSANE-1,23-DIOL

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
5HF9_PE8_B_606	5%	68%	0.34	0.736	0.91	0.33	-	-	1	0	100%	0.72
4EY4_PE8_B_608	71%	41%	0.09	0.909	0.64	1.64	-	1	1	0	100%	1
7XN1_PE8_A_602	49%	57%	0.181	0.93	0.59	1.06	-	1	4	0	100%	1
4EY6_PE8_B_609	36%	39%	0.183	0.877	0.61	1.73	-	1	1	0	100%	0.98
3L9V_PE8_A_1	98%	37%	0.063	0.982	0.59	1.85	-	7	3	0	100%	1
3VND_PE8_D_304	62%	41%	0.165	0.959	0.68	1.6	-	4	5	0	100%	1
7EFJ_PE8_A_202	59%	35%	0.135	0.915	0.92	1.61	2	2	9	0	100%	1
4EF2_PE8_B_303	55%	53%	0.138	0.905	0.78	1.04	-	1	2	0	100%	1
3CMB_PE8_D_269	55%	68%	0.121	0.887	0.51	0.72	-	-	7	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.